X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, AstraZeneca will be able to access Icosavax’s IVX-A12, combination protein VLP vaccine which targets both RSV and human metapneumovirus, two leading causes of severe respiratory infections and hospitalizations in adults 60 years of age and older.
Lead Product(s): IVX-A12
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition February 19, 2024
Details:
Through the acquisition of Icosavax, AstraZeneca gains access to IVX-A12, a combination virus like particle (VLP) vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
Lead Product(s): IVX-A12
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition December 12, 2023
Details:
IVX-A12 is a combination virus like particle (VLP) vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It is under phase 2 clinical development.
Lead Product(s): IVX-A12
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
IVX-A12 (IVX-121, IVX-241) is a vaccine drug candidate, which is being evaluated for the treatment of patients with respiratory syncytial virus infection in adults.
Lead Product(s): IVX-121,IVX-241
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
IVX-A12 is a potential first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses.
Lead Product(s): IVX-121
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-121
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
IVX-A12 is a combination bivalent vaccine candidate against both respiratory syncytial virus and human metapneumovirus. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate.
Lead Product(s): IVX-121,IVX-241
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
IVX-A12 is a combination bivalent vaccine candidate against both respiratory syncytial virus and human metapneumovirus. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate.
Lead Product(s): IVX-121,IVX-241
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
IVX-A12 is a combination bivalent vaccine candidate against both respiratory syncytial virus and human metapneumovirus. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate.
Lead Product(s): IVX-121,IVX-241
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults.
Lead Product(s): IVX-121
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-121
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate.
Lead Product(s): IVX-121,IVX-241
Therapeutic Area: Infections and Infectious Diseases Product Name: IVX-A12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
